Novo Nordisk's Legal Setback and Clinical Scorecard: Why 4 November Matters More Than Any Single Session
Published on 10/31/2026 at 17:31 | Editorial boerse-global.de
Novo Nordisk's attempt to silence Eli Lilly's advertising has failed in a US court, handing the Danish drugmaker a legal defeat just as its commercial and scientific rivalry with its American competitor moves onto several fronts at once. A federal judge on Monday declined to grant a preliminary injunction against Lilly's ads, with Reuters reporting that Novo was unable to demonstrate it would suffer irreparable harm. The ruling leaves the two companies to settle the argument in the marketplace rather than the courtroom.
The scope of that decision deserves care. It concerned a request to block advertising, nothing more, and says nothing about whether one medicine is clinically superior to another. Investors would do well to keep the legal question and the medical one in separate compartments.
A 2.7% Gain That Proves Little
Novo shares rose 2.7% on Friday, a move that coincided with a friendlier tone across the sector following Eli Lilly's quarterly results. No causal link between that report and Novo's advance has been established, and the same caution applies to any attempt to tie the stock's gain to the court order.
What the Lilly numbers do show is pressure. Reuters reported on Thursday that demand for Lilly's injectable weight-loss drugs is running hot, with the company stretching its lead over Novo in the GLP-1 market. Robust demand is a positive signal for the category as a whole, yet it simultaneously sharpens the competitive challenge Novo faces — and sets a demanding benchmark against which its own figures will be read.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Retatrutide Raises the Bar on Efficacy
Advertising is only one theatre of the contest. Reuters reported on Wednesday that Lilly's experimental compound retatrutide delivered better blood-sugar control than Novo's Ozempic in a study of patients with type-2 diabetes, while producing more than double the weight loss. Retatrutide remains investigational, so the finding must not be confused with the question of which treatments are already available to patients. Even so, the data put concrete clinical comparisons alongside the marketing dispute, and Novo's own research output will have to answer them.
A Mixed Bag of Regulatory and Clinical News
The company's recent flow of announcements cuts both ways. On 20 October it released results from a post-hoc analysis of the REDEFINE 1 trial, presented at the annual meeting of the Menopause Society, in which CagriSema was associated with average weight loss of 25% in women. Because the work is a retrospective look at existing trial data, it should not be equated with a fresh approval decision.
One of those did arrive on 23 October, when the FDA cleared Awiqli as the first once-weekly basal insulin for children aged ten and older with type-2 diabetes, according to the company.
November's Two-Part Examination
The calendar now splits into distinct tests. First comes the financial picture: Novo publishes results for the first nine months of 2026 on 4 November, a date that will show whether clinical momentum is translating into commercial progress. Then attention shifts to science, with the company having announced 26 abstracts for ObesityWeek 2026, running from 14 to 17 November in Washington. Those contributions cover CagriSema as well as data on real-world use of the Wegovy tablet.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Novo had already said on Wednesday that it would present new clinical data and practical-care insights on semaglutide at the Liver Meeting, including work on Wegovy and research into the experimental drug efruxifermin.
None of these announcements amounts to pre-released study results, so what the presentations actually demonstrate will be what counts. The court ruling is a setback for Novo's bid to curb a rival's advertising; the research disclosures go to the medical foundation of the competition. And the 4 November print, more than any single trading session, is where the business case will be judged.
Ad
Novo Nordisk Stock: New Analysis - 31 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
